Valneva SE
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas Lingelbach
- Full Time Employees
- 674
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 6 rue Alain Bombard Saint-Herblain GE France 44800
- IPO Date
- Jun 28, 2007
- Website
- valneva.com
- Similar Companies
- Business
- Valneva SE is a France-based specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. Founded in 2013 through the merger of Intercell AG and Vivalis SA, the company is headquartered in Saint-Herblain, France, with manufacturing sites in Livingston, Scotland; Solna, Sweden; and Vienna, Austria, as well as operations across six countries including the United States, Canada, and the United Kingdom. Valneva markets three proprietary commercial vaccines: IXIARO/JESPECT, an inactivated vaccine for the prevention of Japanese encephalitis; DUKORAL, an oral vaccine against cholera and enterotoxigenic Escherichia coli (ETEC) diarrhea; and IXCHIQ, the world's first single-shot live-attenuated vaccine against chikungunya virus, which received FDA approval in 2023 and a positive CHMP opinion in Europe in 2024. The company's vaccine pipeline features three key development programs, including VLA15, the only Lyme disease vaccine candidate in Phase 3 clinical development partnered with Pfizer since 2019; the most advanced Shigella vaccine candidate; and a Zika virus vaccine candidate, supported by technologies such as the EB66 cell line and IC31 adjuvant provided to pharmaceutical partners. In recent developments, Valneva refinanced its debt in October 2025 with a up to $500 million non-dilutive facility from Pharmakon Advisors, repaying prior obligations to Deerfield and OrbiMed while extending maturities to 2030 and lowering costs; reported nine-month 2025 revenues of €127.0 million and cash equivalents of €143.5 million; confirmed its Phase 3 Lyme disease VALOR study remains on track; and adjusted its full-year 2025 outlook to total revenues of €165-180 million with product sales of €155-170 million.
Company News
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Valneva Provides Update on IXCHIQ® in the United Kingdom
Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)
Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)
Valneva: The Lyme Royalty Transition Changes The Earnings Model
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Valneva SE (VALN) Q2 2026 Earnings Call Transcript
Valneva Q2 Earnings Call Highlights
Valneva publie ses résultats financiers du premier semestre 2026 et fait un point sur ses activités
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript
Valneva Announces Successful Outcome of its Annual General Meeting
Valneva Announces Availability of Documentation for its Annual General Meeting
Valneva to Participate at U.S. and European Investor Conferences in June
Valneva annonce sa participation à des conférences investisseurs aux États-Unis et en Europe
Valneva to Participate at U.S. and European Investor Conferences in June
Valneva Q1 Earnings Call Highlights